Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Lyell Immunopharma (LYEL – Research Report) today. The company’s shares opened today at $2.48.
According to TipRanks, Meacham is a 4-star analyst with an average return of 3.0% and a 49.46% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Moderna.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lyell Immunopharma with a $6.00 average price target, which is a 141.94% upside from current levels. In a report released on May 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
The company has a one-year high of $3.97 and a one-year low of $1.32. Currently, Lyell Immunopharma has an average volume of 899.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lyell Immunopharma (LYEL) Company Description:
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors.
